Literature DB >> 11804283

Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type.

Y Hayashi1, M Iwato, Y Arakawa, H Fujisawa, Y Thoma, M Hasegawa, O Tachibana, J Yamashita.   

Abstract

Only a few reports have been published on molecular genetic alterations in primary central nervous system lymphomas (PCNSLs) of the diffuse large B-cell type and no reports have addressed the correlation between the genetic alterations and clinical course of the patients with this neoplasm. Thus, the molecular background of the PCNSL and its importance for the clinical course of the patients are still unclear. We investigated a series of 14 patients with PCNSL to determine structural alterations of the INK4a/ARF, MDM2, and TP53 genes, the status of bcl-2 and bcl-6 protein expression, and the clinical course of the patients (i.e. their survival time after diagnosis). No structural alterations of MDM2 and TP53 genes were found. Only INK4a/ARF genes whose expression affects both the p161NK4a-Rb and p14ARF-mdm2-p53 pathways in the regulation for cell cycle and apoptosis, showed an alteration of the homozygous deletions at a high frequency (nine of 14 patients: 64%). This specific alteration was not related with the bcl-6 expression, but a relation was shown with overexpression of the bcl-2 anti-apoptotic protein (p = 0.036, chi-square test), as well as a shorter patient survival (p = 0.044, Wilcoxon test). There was only a tendency, not a significant correlation, in which the patients with bcl-2 overexpression resulted in poor prognosis (p = 0.149). The present study is the first to suggest that the INK4a/ARF gene homozygous deletions and overexpression of the bcl-2 protein may be correlated with each other and together serve as important predictors for the prognosis of patients with PCNSL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11804283     DOI: 10.1023/a:1012946812930

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.

Authors:  M B Møller; Y Ino; A M Gerdes; K Skjødt; D N Louis; N T Pedersen
Journal:  Leukemia       Date:  1999-03       Impact factor: 11.528

2.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

Authors:  R D Gascoyne; S A Adomat; S Krajewski; M Krajewska; D E Horsman; A W Tolcher; S E O'Reilly; P Hoskins; A J Coldman; J C Reed; J M Connors
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

3.  Transcriptional repression by the proto-oncogene BCL-6.

Authors:  V L Seyfert; D Allman; Y He; L M Staudt
Journal:  Oncogene       Date:  1996-06-06       Impact factor: 9.867

4.  Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.

Authors:  M B Møller; P W Kania; Y Ino; A M Gerdes; O Nielsen; D N Louis; K Skjødt; N T Pedersen
Journal:  Leukemia       Date:  2000-05       Impact factor: 11.528

5.  Primary malignant lymphomas of the central nervous system.

Authors:  J M Henry; R R Heffner; S H Dillard; K M Earle; R L Davis
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

6.  Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989.

Authors:  D C Miller; F H Hochberg; N L Harris; M L Gruber; D N Louis; H Cohen
Journal:  Cancer       Date:  1994-08-15       Impact factor: 6.860

7.  Alterations of the INK4a/ARF locus in human intracranial germ cell tumors.

Authors:  M Iwato; O Tachibana; Y Tohma; Y Arakawa; H Nitta; M Hasegawa; J Yamashita; Y Hayashi
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

8.  Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines.

Authors:  J C Reed; S Kitada; S Takayama; T Miyashita
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

9.  Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS)

Authors:  S Camilleri-Broët; A Martin; A Moreau; R Angonin; D Hénin; M F Gontier; M C Rousselet; S Caulet-Maugendre; P Cuillière; T Lefrancq; K Mokhtari; M Morcos; P Broët; M Kujas; J J Hauw; B Desablens; M Raphaël
Journal:  Am J Clin Pathol       Date:  1998-11       Impact factor: 2.493

Review 10.  Primary central nervous system lymphoma.

Authors:  J W Grant; P G Isaacson
Journal:  Brain Pathol       Date:  1992-04       Impact factor: 6.508

View more
  3 in total

Review 1.  Apoptotic markers for primary brain tumor prognosis.

Authors:  A E Konstantinidou; P Korkolopoulou; E Patsouris
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

2.  Identification of novel genetic alterations in samples of malignant glioma patients.

Authors:  Vedrana Milinkovic; Jasna Bankovic; Miodrag Rakic; Tijana Stankovic; Milica Skender-Gazibara; Sabera Ruzdijic; Nikola Tanic
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

Review 3.  Primary CNS lymphoma.

Authors:  Elizabeth H Phillips; Christopher P Fox; Kate Cwynarski
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.